rethinkPeptides Search
Menu
Study breakdown

Prenatal Nicotine Exposure Increases Substance P Receptor Levels in Lung Nerves, Prolonging Breathing Pauses in Newborn Rats

evidence
The takeaway

Prenatal nicotine exposure upregulated the Substance P receptor (NK1R) and TRPV1 in pulmonary sensory nerves of rat pups, prolonging dangerous breathing pauses that were reversed by blocking NK1R.

NK1R upregulated

Both mRNA and protein levels of the Substance P receptor NK1R were significantly increased in pulmonary sensory neurons of rat pups exposed to nicotine prenatally, mediated through α7 nicotinic receptors

What the researchers found

Prenatal nicotine exposure (PNE) significantly upregulated both mRNA and protein levels of NK1R (Substance P receptor) and TRPV1 in the nodose/jugular ganglia, and NK1R mRNA specifically in pulmonary C-neurons. This upregulation prolonged apneic responses to capsaicin. The NK1R antagonist SR140333 significantly shortened the PNE-induced prolonged apnea, confirming NK1R's functional role.

The mechanism was traced to nicotinic acetylcholine receptors: both mecamylamine (general nAChR antagonist) and methyllycaconitine (selective α7nAChR antagonist) eliminated the PNE-evoked receptor upregulation, identifying α7nAChR as the key mediator of nicotine's effect on peptide receptor expression.

Why it matters

Sudden infant death syndrome (SIDS) and neonatal breathing disorders are more common in babies exposed to nicotine during pregnancy. This study identifies a specific neuropeptide receptor mechanism — NK1R upregulation — that explains how prenatal nicotine sensitizes lung sensory nerves, causing exaggerated and dangerous breathing pauses. This could guide development of interventions for at-risk newborns.

How the study worked

Pregnant rats received nicotine via mini-pump during gestation. Rat pups were studied for: Substance P and adenosine levels in bronchoalveolar lavage fluid, NK1R/ADA1R/TRPV1 expression (mRNA and protein) in nodose/jugular ganglia and retrogradely-labeled pulmonary C-neurons, and apneic responses to intravenous capsaicin with and without NK1R antagonist pretreatment. Additional groups received nAChR antagonists during the prenatal exposure period to identify the upstream mechanism.

What this study cannot tell us

The study was conducted in Sprague-Dawley rats, and the nicotine delivery (mini-pump) does not replicate the intermittent exposure pattern of human smoking. The study focused on acute apneic responses and did not assess long-term respiratory outcomes. Whether NK1R antagonists could safely be used in human neonates is unknown. The relationship between these findings and SIDS risk is inferred, not directly demonstrated.

How to read the evidence

This is a preclinical animal study with thorough mechanistic investigation including gene expression, protein levels, functional assays, and pharmacological validation using specific antagonists. The multi-level evidence is compelling but limited to a rat model.

When this study was published

Published in 2016, this study provides foundational mechanistic understanding of how prenatal nicotine affects neuropeptide receptor expression in the developing respiratory system.

The bigger picture

This study connects prenatal nicotine exposure to neuropeptide receptor dysregulation in the developing lung, providing a molecular explanation for the increased respiratory vulnerability of nicotine-exposed newborns. It adds Substance P/NK1R to the growing list of neuropeptide systems altered by prenatal drug exposure, and identifies a potentially druggable target for preventing nicotine-related neonatal respiratory complications.

Questions still open

  • Could NK1R antagonists be developed as a protective treatment for newborns with known prenatal nicotine exposure?
  • Does vaping/e-cigarette use during pregnancy cause similar NK1R upregulation in fetal lung nerves?
  • Are other neuropeptide receptors in the lung similarly affected by prenatal nicotine, and could they contribute to long-term respiratory disease susceptibility?

Common questions

How does prenatal nicotine cause breathing problems in newborns?
According to this study, nicotine activates α7 nicotinic receptors during fetal development, which increases the number of Substance P receptors (NK1R) on sensory nerve fibers in the lungs. This makes these nerves hypersensitive to stimulation, causing exaggerated and prolonged pauses in breathing (apnea) that could be dangerous for newborns.
Could blocking Substance P receptors help protect at-risk newborns?
In this rat study, blocking NK1R with the antagonist SR140333 significantly shortened the prolonged apnea caused by prenatal nicotine exposure. This suggests NK1R could be a therapeutic target, but significant safety and efficacy testing in human newborns would be needed before this approach could be considered clinically.

Read the original research

Prenatal nicotinic exposure upregulates pulmonary C-fiber NK1R expression to prolong pulmonary C-fiber-mediated apneic response.

Toxicology and applied pharmacology, 290, 107-15

Citation

Zhao, Lei; Zhuang, Jianguo; Zang, Na; Lin, Yong; Lee, Lu-Yuan; Xu, Fadi. (2016). Prenatal nicotinic exposure upregulates pulmonary C-fiber NK1R expression to prolong pulmonary C-fiber-mediated apneic response.. Toxicology and applied pharmacology, 290, 107-15. https://doi.org/10.1016/j.taap.2015.10.023